JP2022534118A5 - - Google Patents

Info

Publication number
JP2022534118A5
JP2022534118A5 JP2021570824A JP2021570824A JP2022534118A5 JP 2022534118 A5 JP2022534118 A5 JP 2022534118A5 JP 2021570824 A JP2021570824 A JP 2021570824A JP 2021570824 A JP2021570824 A JP 2021570824A JP 2022534118 A5 JP2022534118 A5 JP 2022534118A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
fgfr3
infigratinib
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021570824A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022534118A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/035140 external-priority patent/WO2020243442A1/en
Publication of JP2022534118A publication Critical patent/JP2022534118A/ja
Publication of JP2022534118A5 publication Critical patent/JP2022534118A5/ja
Pending legal-status Critical Current

Links

JP2021570824A 2019-05-31 2020-05-29 泌尿器系がんを治療する方法 Pending JP2022534118A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962855277P 2019-05-31 2019-05-31
US62/855,277 2019-05-31
US201962906194P 2019-09-26 2019-09-26
US62/906,194 2019-09-26
PCT/US2020/035140 WO2020243442A1 (en) 2019-05-31 2020-05-29 Methods of treating urinary system cancers

Publications (2)

Publication Number Publication Date
JP2022534118A JP2022534118A (ja) 2022-07-27
JP2022534118A5 true JP2022534118A5 (cg-RX-API-DMAC7.html) 2023-05-19

Family

ID=73553913

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021570824A Pending JP2022534118A (ja) 2019-05-31 2020-05-29 泌尿器系がんを治療する方法

Country Status (12)

Country Link
US (1) US20220233537A1 (cg-RX-API-DMAC7.html)
EP (1) EP3976833A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022534118A (cg-RX-API-DMAC7.html)
KR (1) KR20220088830A (cg-RX-API-DMAC7.html)
CN (1) CN114207151A (cg-RX-API-DMAC7.html)
AU (1) AU2020282816A1 (cg-RX-API-DMAC7.html)
CA (1) CA3141871A1 (cg-RX-API-DMAC7.html)
IL (1) IL288408A (cg-RX-API-DMAC7.html)
MX (1) MX2021014524A (cg-RX-API-DMAC7.html)
PH (1) PH12021552973A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112932QA (cg-RX-API-DMAC7.html)
WO (1) WO2020243442A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3202267A1 (en) * 2020-12-18 2022-06-23 Riccardo Panicucci Methods of treating achondroplasia
CN117982507A (zh) * 2022-11-01 2024-05-07 Qed医药股份有限公司 英菲格拉替尼在治疗胃癌和腺癌中的用途
CN115785001B (zh) * 2022-11-23 2023-09-15 斯坦德药典标准物质研发(湖北)有限公司 一种英菲格拉替尼的制备方法
CN117558346B (zh) * 2023-09-01 2024-12-03 上海仁东医学检验所有限公司 Utuc分子分型及预后预测模型构建方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067968A2 (en) * 2005-12-08 2007-06-14 Novartis Ag Effects of inhibitors of fgfr3 on gene transcription
CA2898326C (en) * 2013-01-18 2022-05-17 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
TWI541022B (zh) * 2013-12-18 2016-07-11 應克隆公司 針對纖維母細胞生長因子受體-3(fgfr3)之化合物及治療方法
CN103757026B (zh) * 2013-12-20 2017-04-05 广州圣露生物技术有限公司 FGFR2b胞外段的基因序列、多肽及其应用
SG11201702381QA (en) * 2014-09-26 2017-04-27 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
CN110785184A (zh) * 2017-02-06 2020-02-11 雷尼尔医疗公司 用于治疗癌症的方法,组合物和试剂盒
KR20250047324A (ko) * 2017-08-07 2025-04-03 더 존스 홉킨스 유니버시티 암을 평가하고 치료하기 위한 방법 및 재료
MA47408B1 (fr) * 2017-12-20 2023-08-31 Janssen Pharmaceutica Nv Traitement du cancer

Similar Documents

Publication Publication Date Title
JP2024530310A (ja) T細胞リンパ腫治療薬の調製におけるezh2阻害剤の使用
Spitler A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma.
JP5952890B2 (ja) 膵臓癌を治療するための医薬製剤
JP2019081792A5 (cg-RX-API-DMAC7.html)
Cho et al. Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer
JP6462147B2 (ja) Hsp90阻害ペプチド結合体及びその腫瘍治療における応用
JP2023513704A5 (cg-RX-API-DMAC7.html)
CN111184863B (zh) 酪氨酸激酶抑制剂、cdk4/6抑制剂、serd联合在制备治疗肿瘤的药物中的用途
WO2015185011A1 (zh) 喹啉衍生物用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物
US20190175598A1 (en) Combination therapies for the treatment of hepatocellular carcinoma
TW201300107A (zh) 組合療法
CN107308164A (zh) 辅助癌症治疗的方法
BR112019015023A2 (pt) Intensificadores de canibalismo celular para uso para sensibilizar tumores para terapia por radiação
WO2017148129A1 (zh) 一种用于治疗恶病质的药物组合物及其应用
TW202110454A (zh) Cdk4/6抑制劑與vegfr抑制劑聯合在製備治療腫瘤的藥物中的用途
CN109303781A (zh) 川穹嗪在制备治疗子宫内膜异位症的药物中的应用
ES2554332T3 (es) Utilización de la bencidamina en el tratamiento de las enfermedades dependientes de p40
WO2023281413A1 (en) Methods and dosing regimens comprising pf-06873600 for the treatment of cancer
CN112826820B (zh) Nlrp3抑制剂及其应用
JP2025509613A5 (cg-RX-API-DMAC7.html)
CN109963847A (zh) 治疗实体瘤的方法
CN111728960B (zh) 富马酸比索洛尔联合多西他赛在制备抗肿瘤药物中的应用
CN111388665B (zh) 一种治疗肿瘤的复合物及其制剂和用途
CN110339195A (zh) 用于治疗胆管癌的喹啉衍生物
CN118354772A (zh) 治疗头颈癌的方法